Role of glycosaminoglycans in the regulation of T cell proliferation induced by thymic stroma-derived T cell growth factor.
The present study investigates the regulatory effects of glycosaminoglycans such as heparin and heparan sulfate on T cell proliferation induced by thymic stromal cell monolayer or its derived T cell growth factor (TCGF). A thymic stromal cell clone (MRL104.8a) supported the growth of Ag-specific, IL-2-dependent Th cell clone (9-16) in the absence of Ag and IL-2 by producing a unique TCGF designated as thymic stroma-derived T cell growth factor (TSTGF). The addition of heparin to cultures in which the growth of 9-16 Th cells was otherwise stimulated by the MRL104.8a monolayer or a semipurified sample of the TSTGF resulted in heparin dose-dependent inhibition of 9-16 Th proliferation. The dose of heparin required for inducing 50% reduction of TSTGF-induced proliferation of Th at a given cell number was found to be proportional to the magnitude of the TSTGF added to cultures, suggesting that heparin exerted its inhibitory effect by binding to the TSTGF rather than by acting on Th cells. A similar growth-inhibiting effect of heparin was observed in IL-7-dependent proliferation of pre-B cell line or Th, but not in IL-2-dependent T cell proliferation or IL-3-dependent myeloid cell proliferation. A strong affinity of TSTGF and IL-7 for heparin was confirmed by the fact that both TSTGF and IL-7 adhered to columns of heparin-agarose and were eluted by salt. When various glycosaminoglycans were tested for the heparin-like Th growth-regulatory capacity, heparan sulfate exhibited Th growth-inhibiting ability comparable to that observed for heparin. These results indicate that the activity of thymic and/or bone marrow stroma-derived lymphocyte growth factor (TSTGF/IL-7) but not of Th-producing TCGF (IL-2) is negatively regulated by heparin or heparan sulfate, which would represent major glycosaminoglycans in the extra-cellular matrix of stromal cells.
Kimura
K
K
Biomedical Research Center, Osaka University Medical School, Japan.
Matsubara
H
H
Sogoh
S
S
Kita
Y
Y
Sakata
T
T
Nishitani
Y
Y
Watanabe
S
S
Hamaoka
T
T
Fujiwara
H
H
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents; D001402:B-Lymphocytes / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002809:Chondroitin Sulfates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006025:Glycosaminoglycans / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D006497:Heparan Sulfate / Q000494:pharmacology; D006820:Hyaluronic Acid / Q000494:pharmacology; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000378:metabolism / Q000494:pharmacology* / Q000502:physiology; D015851:Interleukin-7 / Q000378:metabolism / Q000502:physiology; D007632:Keratan Sulfate / Q000494:pharmacology; D051379:Mice; D013601:T-Lymphocytes / Q000378:metabolism / Q000502:physiology*; D013950:Thymus Gland / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D002809:Chondroitin Sulfates; D006025:Glycosaminoglycans; D006493:Heparin; D006497:Heparan Sulfate; D006820:Hyaluronic Acid; D007376:Interleukin-2; D015851:Interleukin-7; D007632:Keratan Sulfate